SCHEMBL13738641

SCHEMBL13738641

O=C(CCl)c1cc(-c2ccc(Cl)cc2)ns1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 8/20 0.44
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
JAK2 O60674 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPK1 P28482 1/20 0.40
HIF1A Q16665 1/20 0.40
KMO O15229 1/20 0.39
CA12 O43570 1/20 0.39
ALPL P05186 1/20 0.39
CTRC Q99895 2/20 0.38
CASP1 P29466 1/20 0.38
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
ALAD P13716 1/20 0.37
NOTUM Q6P988 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740513 0.82 ALAD (0.51) ALDH1A1SMN1; SMN2HIF1AKMOCA12
SCHEMBL13832709 0.78 USP14 (0.46) ALDH1A1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL11001807 0.77 MAPT (0.54) ALDH1A1SMN1; SMN2L3MBTL1ALPLTP53
SCHEMBL11387968 0.77 ALPL (0.56) ALDH1A1SMN1; SMN2MAPK1ALPLCASP1
SCHEMBL21479795 0.76 TDP1 (0.40) ALDH1A1SMN1; SMN2HTTL3MBTL1MAPK1
SCHEMBL27952223 0.72 ADORA3 (0.39) ALDH1A1SMN1; SMN2JAK2HTTL3MBTL1
SCHEMBL28567224 0.71 NOTUM (0.45) ALDH1A1SMN1; SMN2JAK2HTTL3MBTL1
SCHEMBL27667553 0.71 ALOX5 (0.41) ALDH1A1SMN1; SMN2HTTMAPK1KMO
SCHEMBL8880792 0.70 ADORA1 (0.48) ALDH1A1SMN1; SMN2HTTL3MBTL1MAPK1
SCHEMBL6988848 0.69 KMO (0.42) ALDH1A1SMN1; SMN2L3MBTL1HIF1AKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12180189-B2 Proteostasis regulators Kineta, Inc. (US) 2024-12-31 US disclosed
US-20200299270-A1 PROTEOSTASIS REGULATORS Kineta, Inc. 2020-09-24 US disclosed
US-20200299270-A1 PROTEOSTASIS REGULATORS Kineta, Inc. 2020-09-24 US disclosed
EP-3552664-A1 PROTEOSTASIS REGULATORS Proteostasis Therapeutics, Inc. (US) 2019-10-16 EP disclosed
EP-2707101-B1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS INC (US) 2019-02-13 EP disclosed
EP-2707101-B1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS INC (US) 2019-02-13 EP disclosed
US-20170247355-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2017-08-31 US disclosed
US-20170247355-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2017-08-31 US disclosed
US-20170247355-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2017-08-31 US disclosed
US-9556166-B2 Proteostasis regulators PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-01-31 US disclosed
US-9556166-B2 Proteostasis regulators PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-01-31 US disclosed
US-9556166-B2 Proteostasis regulators PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-01-31 US disclosed
EP-2707101-A1 PROTEOSTASIS REGULATORS Proteostasis Therapeutics, Inc. (US) 2014-03-19 EP disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 US disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 US disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 US disclosed
WO-2012154967-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 WO disclosed
WO-2012154967-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299270-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 GSK3B 2472/4885ALDH1A1 3419/4885SMN1; SMN2 595/4885
US-20170247355-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 GSK3B 2472/4885ALDH1A1 3419/4885SMN1; SMN2 595/4885
US-12180189-B2 Proteostasis regulators PSMG3, VCP, HSPA5 GSK3B 2472/4885ALDH1A1 3419/4885SMN1; SMN2 595/4885
US-20120316193-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 GSK3B 2472/4885ALDH1A1 3419/4885SMN1; SMN2 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.